ESTRO meets Asia 2024 - Abstract Book

S186

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

Conclusion:

The benefit of the addition of chemotherapy to RT using weekly cisplatin was not clearly observed in the prognosis of elderly patients with LA-HNSCC. Prospective randomized trials are needed to verify our findings.

Keywords: chemoradiotherapy, cisplatin, elderly patients

References:

1. Benjamin L, Alexandra C, Cécile L, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281-293. 2. Shinohara S, Takebayashi S, Hamaguchi K, et al. Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma. Clin Med Insights Oncol. 2021;15: 11795549211048417.

3. Uchimaki Y, Yasuda K, Kano S, et al. Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma. Discov Oncol. 2023;14(1):226.

4. Koichi Yasuda, Yusuke Uchinami, Satoshi Kano, et al. Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan. Int J Clin Oncol. 2024 Mar;29(3):241-247.

355

Digital Poster

EVALUATION OF EXTENT OF ENE AND PNI ON SURVIVAL OUTCOMES IN ORAL CAVITY SCC TREATED WITH ADJUVANT RT Sambit Swarup Nanda, shubham Dokania, Ashutosh Mukherji, Ajay S Krishnan, Ajay Choubey, Ninad H Patil, Pritam Mondal, Satyajit Pradhan

Radiation Oncology, HBCH & MPMMCC, Varanasi, India